The cardiovascular risk of tiotropium: is it real?

Bibliography

• Celli BR, MacNee W, Agusti A, Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-46
   PubMed Web of Science ®Google Scholar
• Rabe KF, Hurd S, Anzueto A, Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-55
   PubMed Web of Science ®Google Scholar
• Calverley PMA, Anderson JA, Celli B, Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Senn S, A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-54
   PubMed Web of Science ®Google Scholar
• Cazzola M. From large clinical trials to management of COPD in the real world. Ther Adv Respir Dis 2009;3:39-46
   PubMedGoogle Scholar
• Barnes PJ. The role of anticholinergics in chronic obstructive pulmonary disease. Am J Med 2004;117(Suppl 12A):24S-32S
   PubMedGoogle Scholar
• Currie GP, Rossiter C, Miles SA, Effects of tiotropium and other long acting bronchodilators in chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2006;19(2):112-9
   PubMed Web of Science ®Google Scholar
• Chen AM, Bollmeier SG, Finnegan PM. Long-acting bronchodilator therapy for the treatment of chronic obstructive pulmonary disease. Ann Pharmacother 2008;42:1832-42
   PubMed Web of Science ®Google Scholar
• Salpeter SR. Do inhaled anticholinergics increase or decrease the risk of major cardiovascular events?: a synthesis of the available evidence. Drugs 2009;69:2025-33
   PubMed Web of Science ®Google Scholar
• Anthonisen NR, Connett JE, Enright PL, Manfreda J. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002;166:333-9
   PubMed Web of Science ®Google Scholar
• Lanes S, Golisch W, Mikl J. Ipratropium and lung health study. Am J Respir Crit Care Med 2003;167:801-2
   PubMed Web of Science ®Google Scholar
• Lee TA, Pickard AS, Au DH, Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med 2008;149:380-90
   PubMed Web of Science ®Google Scholar
• Ogale SS, Lee TA, Au DH, Cardiovascular events associated with ipratropium bromide in COPD. Chest 2010;137:13-9
   PubMed Web of Science ®Google Scholar
• Sin DD, Tu JV. Lack of association between ipratropium bromide and mortality in elderly patients with chronic obstructive airway disease. Thorax 2000;55:194-7
   PubMed Web of Science ®Google Scholar
• Brodde OE, Bruck H, Leineweber K, Seyfarth T. Presence, distribution and physiological function of adrenergic and muscarinic receptor subtypes in the human heart. Basic Res Cardiol 2001;96:528-38
   PubMed Web of Science ®Google Scholar
• Hellgren I, Mustafa A, Riazi M, Muscarinic M3 receptor subtype gene expression in the human heart. Cell Mol Life Sci 2000;57:175-80
   PubMed Web of Science ®Google Scholar
• Oberhauser V, Schwertfeger E, Rutz T, Acetylcholine release in human heart atrium: influence of muscarinic autoreceptors, diabetes, and age. Circulation 2001;103:1638-43
   PubMed Web of Science ®Google Scholar
• Wang H, Han H, Zhang L, Expression of multiple subtypes of muscarinic receptors and cellular distribution in the human heart. Mol Pharmacol 2001;59:1029-36
   PubMed Web of Science ®Google Scholar
• Myslivecek J, Klein M, Novakova M, Ricny J. The detection of the non-M2 muscarinic receptor subtype in the rat heart atria and ventricles. Naunyn Schmiedebergs Arch Pharmacol 2008;378:103-16
   PubMed Web of Science ®Google Scholar
• Dhein S, van Koppen CJ, Brodde OE. Muscarinic receptors in the mammalian heart. Pharmacol Res 2001;44:161-82
   PubMed Web of Science ®Google Scholar
• Olshansky B, Sabbah HN, Hauptman PJ, Colucci WS. Parasympathetic nervous system and heart failure: pathophysiology and potential implications for therapy. Circulation 2008;118:863-71
   PubMed Web of Science ®Google Scholar
• Li M, Zheng C, Sato T, Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation 2004;109:120-4
   PubMed Web of Science ®Google Scholar
• Bymaster FP, Carter PA, Zhang L, Investigations into the physiological role of muscarinic M2 and M4 muscarinic and M4 receptor subtypes using receptor knockout mice. Life Sci 2001;68:2473-9
   PubMed Web of Science ®Google Scholar
• Wang H, Shi H, Lu Y, Pilocarpine modulates the cellular electrical properties of mammalian hearts by activating a cardiac M3 receptor and a K+ current. Br J Pharmacol 1999;126:1725-34
   PubMed Web of Science ®Google Scholar
• Wang H, Lu Y, Wang Z. Function of cardiac M3 receptors. Auton Autacoid Pharmacol 2007;2:1-11
   Google Scholar
• Stengel PW, Yamada M, Wess J, Cohen ML. M3-receptor knockout mice: muscarinic receptor function in atria, stomach fundus, urinary bladder, and trachea. Am J Physiol Regul Integr Comp Physiol 2002;282:R1443-9
   PubMed Web of Science ®Google Scholar
• Shi H, Wang H, Li D, Differential alterations of receptor densities of three muscarinic acetylcholine receptor subtypes and current densities of the corresponding K+ channels in canine atria with atrial fibrillation induced by experimental congestive heart failure. Cell Physiol Biochem 2004;14:31-40
   PubMed Web of Science ®Google Scholar
• Tuomi JM, Chidiac P, Jones DL. Evidence for enhanced M3 muscarinic receptor function and sensitivity to atrial arrhythmia in the RGS2-deficient mouse. Am J Physiol Heart Circ Physiol 2010;298:H554-61
   PubMed Web of Science ®Google Scholar
• Lamping KG, Wess J, Cui Y, Muscarinic (M) receptors in coronary circulation: gene-targeted mice define the role of M2 and M3 receptors in response to acetylcholine. Arterioscler Thromb Vasc Biol 2004;24:1253-8
   PubMed Web of Science ®Google Scholar
• Wellstein A, Pitschner HF. Complex dose–response curves of atropine in man explained by different functions of M1- and M2-cholinoceptors. Naunyn Schmiedebergs Arch Pharmacol 1988;338:19-27
   PubMed Web of Science ®Google Scholar
• Pitschner HF, Schlepper M, Schulte B, Selective antagonists reveal different functions of M cholinoceptor subtypes in humans. Trends Pharmacol Sci 1989;(Suppl):92-6
   PubMedGoogle Scholar
• LaCroix C, Freeling J, Giles A, Deficiency of M2 muscarinic acetylcholine receptors increases susceptibility of ventricular function to chronic adrenergic stress. Am J Physiol Heart Circ Physiol 2008;294:H810-20
   PubMed Web of Science ®Google Scholar
• Bruck H, Ulrich A, Gerlach S, Effects of atropine on human cardiac beta1- and/or beta2-adrenoceptor stimulation. Naunyn Schmiedebergs Arch Pharmacol 2003;367:572-7
   PubMed Web of Science ®Google Scholar
• Rigel D, Lipson D, Katona P. Excess tachycardia: heart rate after antimuscarinic agents in conscious dogs. Am J Physiol 1984;246(Heart Circ Physiol 15) H168-73
   PubMedGoogle Scholar
• Bauer R, Paschmann S, Wick S. Effect of (8r)-3alpha-hydroxy 8-isopropyl-lalphaH, 5alphaH-tropaniumbromide-(+)-tropate (ipratropium bromide) on tracheobronchial spasm, bronchial and salivary secretions, ECG and heart rate. Arzneimittelforsch 1976;26:981-5
   PubMed Web of Science ®Google Scholar
• Libersa CC, Caron JF, Kacet S, Comparative cardiac effects of intravenous bolus of ipratropium bromide (itrop) and atropine sulfate in 22 patients. Clin Cardiol 1988;11:454-60
   PubMed Web of Science ®Google Scholar
• Kikis D, Esser H, Heinrich K. Influence of ipratropium bromide on heart rate and hemodynamics in patients with sinus bradycardia. Clin Cardiol 1982;5:441-5
   PubMed Web of Science ®Google Scholar
• Lehrer PM, Hochron SM, Rausch L, Carr R. Effects of aerosol ipratropium bromide on cardiac vagal tone. Chest 1994;105:1701-4
   PubMed Web of Science ®Google Scholar
• Ayer A, Antic V, Dulloo AG, Hemodynamic consequences of chronic parasympathetic blockade with a peripheral muscarinic antagonist. Am J Physiol Heart Circ Physiol 2007;293:H1265-72
   PubMed Web of Science ®Google Scholar
• Dunlap ME, Bibevski S, Rosenberry TL, Ernsberger P. Mechanisms of altered vagal control in heart failure: influence of muscarinic receptors and acetylcholinesterase activity. Am J Physiol Heart Circ Physiol 2003;285:H1632-40
   Google Scholar
• Azevedo ER, Parker JD. Parasympathetic control of cardiac sympathetic activity: normal ventricular function versus congestive heart failure. Circulation 1999;100:274-9
   PubMed Web of Science ®Google Scholar
• Disse B, Speck GA, Rominger KL, Tiotropium: mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 1999;64:457-64
   PubMed Web of Science ®Google Scholar
• Koumis T, Samuel S. Tiotropium bromide: a new long-acting bronchodilator for the treatment of chronic obstructive pulmonary disease. Clin Ther 2005;27:377-92
   PubMed Web of Science ®Google Scholar
• Covelli H, Bhattacharya S, Cassino C, Absence of electrocardiographic findings and improved function with once-daily tiotropium in patients with chronic obstructive pulmonary disease. Pharmacotherapy 2005;25:1708-18
   PubMed Web of Science ®Google Scholar
• Morganroth J, Golisch W, Kesten S. Eletrocardiographic monitoring in COPD patients receiving tiotropium. COPD 2004;1:181-90
   PubMedGoogle Scholar
• Kesten S, Jara M, Wentworth C, Lanes S. Pooled clinical trial analysis of tiotropium safety. Chest 2006;130:1695-703
   PubMed Web of Science ®Google Scholar
• Travers J, Laveneziana P, Webb KA, Effect of tiotropium bromide on the cardiovascular response to exercise in COPD. Respir Med 2007;101:2017-24
   PubMed Web of Science ®Google Scholar
• de Luise C, Lanes SF, Jacobsen J, Cardiovascular and respiratory hospitalizations and mortality among users of tiotropium in Denmark. Eur J Epidemiol 2007;22:267-72
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300:1439-50
   PubMed Web of Science ®Google Scholar
• Barr RG, Bourbeau J, Camargo CA, Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 2006;61:854-62
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Early Communication about an Ongoing Safety Review of Tiotropium; 2008. Available from: www.fda.gov/cder/drug/early_comm/tiotropium.htm. [Accessed October 2008]
   Google Scholar
• Wedzicha JA, Calverley PM, Seemungal TA, The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19-26
   PubMed Web of Science ®Google Scholar
• Celli B, Decramer M, Kesten S, Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180:948-55
   PubMed Web of Science ®Google Scholar
• Grosso A, Douglas I, Hingorani AD, Inhaled tiotropium bromide and risk of stroke. Br J Clin Pharmacol 2009;68:731-6
   PubMed Web of Science ®Google Scholar
• Oba Y, Zaza T, Thameem DM. Safety, tolerability and risk benefit analysis of tiotropium in COPD. Int J Chron Obstruct Pulmon Dis 2008;3:575-84
   PubMedGoogle Scholar
• Salpeter SR. Do inhaled anticholinergics increase or decrease the risk of major cardiovascular events? A synthesis of the available evidence. Drugs 2009;69:2025-33
   PubMed Web of Science ®Google Scholar
• Moher D, Cook DJ, Eastwood S, Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Lancet 1999;354:1896-900
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Castro-Rodriguez JA, Nannini LJ, Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta-analysis. Respir Med 2009;103:1421-9
   PubMed Web of Science ®Google Scholar
• Celli B, Decramer M, Leimer I, Cardiovascular safety of tiotropium in patients with COPD. Chest 2010;137:20-30
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Meeting of the Pulmonary-Allergy Drugs Advisory Committee. Available from: www.fda.gov/.../CommitteesMeetingMaterials/ Drugs/Pulmonary-AllergyDrugsAdvisory Committee/UCM194082.pdf. [Accessed 28 May 2010]
   Google Scholar
• Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of ß-agonists in patients with asthma and COPD: a meta-analysis. Chest 2004;125:2309-21
   PubMed Web of Science ®Google Scholar
• Cazzola M, Imperatore F, Salzillo A, Chest 1998;114:411-5
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG, Donner CF. Inhaled ß2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease. Drugs 2005;65:1595-610
   PubMed Web of Science ®Google Scholar
• Jara M, Lanes SF, Wentworth C III, Comparative safety of long-acting inhaled bronchodilators: a cohort study using the UK THIN primary care database. Drug Saf 2007;30:1151-60
   PubMed Web of Science ®Google Scholar
• Sakamaki F, Satoh T, Nagaya N, Abnormality of left ventricular sympathetic nervous function assessed by 123I-metaiodobenzylguanidine imaging in patients with COPD. Chest 1999;116:1575-81
   PubMed Web of Science ®Google Scholar
• Stewart AG, Marsh F, Waterhouse JC, Autonomic nerve dysfunction in COPD as assessed by the acetylcholine sweat-spot test. Eur Respir J 1994;7:1090-5
   PubMed Web of Science ®Google Scholar
• Cazzola M, Bettoncelli G, Sessa E, Prevalence of comorbidities in patients with chronic obstructive pulmonary disease. Respiration 2010; In press
   Google Scholar
• Curkendall SM, DeLuise C, Jones JK, Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006;16:63-70
   PubMed Web of Science ®Google Scholar
• Macie C, Wooldrage K, Manfreda J, Anthonisen N. Cardiovascular morbidity and the use of inhaled bronchodilators. Int J Chron Obstruct Pulmon Dis 2008;3:163-9
   PubMedGoogle Scholar
• Rabe KF. Anticholinergic drugs for the treatment of COPD are safe... are they? Chest 2010;137:1-3
   PubMed Web of Science ®Google Scholar
• Heredia JL. Tiotropium bromide: an update. Open Respir Med J 2009;3:43-52
   PubMedGoogle Scholar
• Cazzola M, Matera MG. Should long-acting ß2-agonists be considered an alternative first choice option for the treatment of stable COPD? Respir Med 1999;93:227-9
   PubMed Web of Science ®Google Scholar
• Vukajlovic DD, Guettler N, Miric M, Pitschner HF. Effects of atropine and pirenzepine on heart rate turbulence. Ann Noninvasive Electrocardiol 2006;11:34-7
   PubMed Web of Science ®Google Scholar
• Marine JE, Watanabe MA, Smith TW, Monahan KM. Effects of atropine on heat rate turbulence. Am J Cardiol 2002;89:767-9
   PubMed Web of Science ®Google Scholar
• Au D, Lemaitre R, Curtis J, The risk of myocardial infarction associated with inhaled ß-adrenoceptor agonists. Am J Respir Crit Care Med 2000;161:827-30
   PubMed Web of Science ®Google Scholar